// App-Quantinova.ai

231 : Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.

Researchers

Presenter

  • Vincenza Conteduca

Principal Investigators

  • Simon J. Crabb

  • Emanuela Scarpi

  • Catherine Hanna

  • Francesca Maines

  • Helen Joyce

  • Paolo Fabbri

  • Lisa Derosa

  • Francesco Massari

  • Cristian Lolli

  • Sunnya Zarif

  • Robert J. Jones

  • Orazio Caffo

  • Tony Elliott

  • Ugo De Giorgi

Medical Centers

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • University of Southampton, Southampten, United Kingdom

  • IRST-IRCCS, Meldola (FC), Italy, Meldola, Italy

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Santa Chiara Hospital, Trento, Italy

  • The Christie Hospital, Manchester, United Kingdom

  • Infermi Hospital, Rimini, Italy

  • Oncology Unit 2, University Hospital of Pisa, Pisa, Italy

  • Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

  • Lactate dehydrogenase

Drug/Treatment

  • Enzalutamide

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved